Intestinal Cell News Volume 5.40 | Oct 25 2019

TOP STORY

A Novel BMI-1 Inhibitor QW24 for the Treatment of Stem-Like Colorectal Cancer

Colorectal cancer stem-like cell lines HCT116 and HT29 were used for screening more than 500 synthetic compounds by sulforhodamine B (SRB) cell proliferation assay. The candidate compound was studied in vitro by SRB cell proliferation assay, western blotting, cell colony formation assay, quantitative real-time PCR, flow cytometry analysis, and transwell migration assay. [J Exp Clin Cancer Res] Full Article

(Ranked by impact factor of the journal)

Induction Apoptosis of Erinacine A in Human Colorectal Cancer Cells Involving the Expression of TNFR, Fas, and Fas Ligand via the JNK/p300/p50 Signaling Pathway With Histone Acetylation

Researchers found that treatment with erinacine A not only triggered the activation of extrinsic apoptosis pathways but also suppressed the expression of antiapoptotic molecules Bcl-2 and Bcl-XL via a time-dependent manner in DLD-1 cells. Furthermore, phosphorylation of Jun N-terminus kinase (JNK1/2), NFκB p50, and p300 was involved in erinacine A-induced cancer cell apoptosis. [Front Pharmacol] Full Article

CD44/CD133-Positive Colorectal Cancer Stem Cells Are Sensitive to Trifluridine Exposure

CD44⁺CD133⁺ high-expressing and other populations of human DLD-1 colon cancer cells were separately isolated through fluorescence-activated cell sorting. The sphere-forming activity of each population and the anti-sphere-forming effects of trifluridine and fluorouracil on CD44⁺CD133⁺ cells were then measured. [Sci Rep] Full Article

Mithramycin a Inhibits Colorectal Cancer Growth by Targeting Cancer Stem Cells

Scientists showed for the first time that mithramycin A can successfully inhibit cancer stem cell proliferation, in addition to inhibiting bulk cancer cells in a model of colorectal cancer (CRC). To this end, a polymeric nanofiber scaffold culture system was established to develop 3D tumor organoids from CRC cell lines such as HT29, HCT116, KM12, CT26 and MC38 as well as ex vivo mouse tumors. [Sci Rep] Full Article

Integrin-EGFR Interaction Regulates Anoikis Resistance in Colon Cancer Cells

The authors report that highly metastatic colon cancer cells showed a higher degree of anoikis resistance than the normal intestinal epithelial cells. These anoikis-resistant cancer cells expressed high-levels of integrin-α2, β1, and activated EGFR in the anchorage-independent state than the anchorage-dependent state. [Apoptosis] Abstract

BH3 Profiling Discriminates the Anti-Apoptotic Status of 5-Fluorouracil-Resistant Colon Cancer Cells

To identify the mechanism of 5-fluorouracil (5-FU) resistance, investigators established three 5-FU-resistant colon cancer cell lines and analyzed both apoptosis-related protein expression levels and BH3 profiling. These 5-FU-resistant colon cancer cell lines acquired apoptotic resistance to 5-FU. [Oncol Rep] Abstract | Download Full Article

Ethanol Extract of Chrysanthemum zawadskii Herbich Induces Autophagy and Apoptosis in Mouse Colon Cancer Cells through the Regulation of Reactive Oxygen Species

Using Chrysanthemum zawadskii Herbich (ECZ) on mouse colon cancer CT-26 cells, cell viability, annexin V/propidium iodide staining, acridine orange staining, reactive oxygen species and western blotting were assayed. ECZ exhibited cytotoxicity in CT-26 cells in a dose-dependent manner. [BMC Complement Altern Med] Full Article

Study of the Protective Effect on Damaged Intestinal Epithelial Cells of Rat Multilineage-Differentiating Stress-Enduring (Muse) Cells

Rat Muse cells were separated from bone-marrow mesenchymal stem cells (BMMSCs) by trypsin-incubation stress. The group of cells maintained the characteristics of BMMSCs; however, there were high positive expression levels of stage-specific embryonic antigen-3 and stage-specific embryonic antigen-1, as well as specific antigens including Nanog, POU class 5 homeobox 1, and SRY-box 2. [Cell Biol Int] Abstract

Cyclization of Flavokawain B Reduces Its Activity Against Human Colon Cancer Cells

Strong cytotoxic activity of flavokawain B and its ability to inhibit the proliferation in both cell lines was detected. These effects accompanied with induction cell cycle arrest in G2/M phase and the presence of SubG1 fraction. [Hum Exp Toxicol] Abstract

Subscribe to one of our other 19 science newsletters such as Pulmonary Cell News & ESC & iPSC News.

Immune Checkpoint Inhibitors for the Treatment of MSI-H/MMR-D Colorectal Cancer and a Perspective on Resistance Mechanisms

Investigators discuss the clinical trials that established the efficacy of immune checkpoint inhibitors in patients with microsatellite instability-high/mismatch repair-deficiency colorectal cancer, consider biomarkers of the immune response and elaborate on potential mechanisms related to intrinsic and acquired resistance. They also provide a perspective on possible future therapeutic approaches that might improve clinical outcomes, particularly in patients with actionable resistance mechanisms. [Br J Cancer] Abstract

Human Colorectal Cancer From the Perspective of Mouse Models

The authors present mouse intestinal cancer models that include alterations in the Wnt, Hippo, p53, epidermal growth factor, and transforming growth factor β pathways; models of impaired DNA mismatch repair and chemically induced tumorigenesis are included. [Genes (Basel)] Abstract

Visit our reviews page to see a complete list of reviews in the intestinal cell research field.

Janssen Announces US FDA Approval of STELARA^® (Ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

The Janssen Pharmaceutical Companies of Johnson & Johnson announced FDA approval of STELARA^® for the treatment of adult patients with moderately to severely active ulcerative colitis. The approval for this new indication is based on the pivotal Phase III UNIFI clinical trial which achieved its primary endpoint of clinical remission. [The Janssen Pharmaceutical Companies of Johnson & Johnson] Press Release

Takeda Acquires License for First-in-Class Celiac Disease Therapy from COUR Pharmaceuticals following Positive Phase IIa Proof-of-Concept Study

Takeda Pharmaceutical Company Limited and COUR Pharmaceutical Development Company, Inc. announced that Takeda has acquired an exclusive global license to develop and commercialize the investigational medicine CNP-101/TAK-101, an immune modifying nanoparticle containing gliadin proteins. [Takeda Pharmaceutical Company Limited (Business Wire, Inc.)] Press Release

Argentine Scientists Rally Behind Favorite in Sunday’s Presidential Election

Thousands of Argentine scientists are hoping the man expected to be the country’s next president will reverse deep cuts to research imposed by the conservative government of President Mauricio Macri. But the first priority for Alberto Fernández, the front-runner inOctober 27^th‘s election, will almost certainly be Argentina’s crumbling economy. And it’s not clear when- or how effectively- the concerns of scientists will be addressed. [ScienceMagazine] Editorial

German University Finds ‘Severe’ Misconduct by Researcher Who Promoted Questionable Cancer Blood Test

A university commission announced this week it had found evidence of “extensive and severe scientific misconduct” by Christof Sohn, director of the women’s clinic at Heidelberg University Hospital in Germany and the lead researcher behind a highly publicized but questionable blood test designed to detect breast cancer. [ScienceMagazine] Editorial

Some of NIH’s Chimpanzees Will Not Retire to a Sanctuary as Planned

The US National Institutes of Health (NIH) will not be retiring all of its chimpanzees to a sanctuary, as it originally pledged to do, agency head Francis Collins announced today. Nearly four dozen chimps at a biomedical primate facility in New Mexico will remain there because they are too old and sick to move, he said, although scientific studies of them have ended. [ScienceMagazine] Editorial

NEW Gene Regulation: From Mechanisms to Disease
January 26-30, 2020
Keystone, Colorado, United States

Visit our events page to see a complete list of events in the community.

NEW PhD Student – Gut Microbiota on Intestinal Inflammation (Flanders Institute for Biotechnology)

NEW Research Fellow – Intestinal In Vivo/In Vitro Correlations (AbbVie)

Postdoctoral Fellow – Gut Microbiome & IBD (Case Western Reserve University)

Postdcotoral Scientist – iPSC Models of Intestinal Fibrosis (Cedars-Sinai Medical Center)

Postdoctoral Fellow – Toxic Injury Research (The University of Cambridge)

Assistant Professors – Microbiome Research (University of Illinois at Urbana-Champaign)

Senior Scientist – Immunology and Gastroenterology (Johnson & Johnson)

Research Scientist – In Vivo Research on Wnt Signaling in Self-Renewel (Surrozen)

Postdoctoral Fellow – Intestinal Graft-versus-Host-Disease (Medical College of Wisconsin)

Principal Researcher – Systems Disease Biology (Boehringer Ingelheim)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Intestinal Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.